Aptevo Therapeutics Inc.
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -23.74% | 13.29% | 13.92% | -15.77% | 6.79% |
| Total Depreciation and Amortization | -15.48% | -7.69% | -14.15% | -8.62% | -5.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -148.32% | -45.42% | -62.03% | 100.84% | -21.32% |
| Change in Net Operating Assets | 256.50% | 44.16% | 1.25% | -464.77% | 136.29% |
| Cash from Operations | -10.28% | 15.13% | 7.49% | -26.61% | 15.82% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 36.89% | 23.65% | -- | -- | -29.83% |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | 36.89% | 23.68% | 132,400.00% | -100.10% | -29.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 407.03% | 85.67% | 67.18% | -201.50% | -16.40% |